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Abstract: KTM is a 16 amino acid peptide with the sequence WCCSYPGCYWSSSKWC. Here,
we present the nuclear magnetic resonance (NMR) structure and bioactivity of this rationally
designed α-conotoxin (α-CTx) that demonstrates potent inhibition of rat α3β2-nicotinic acetylcholine
receptors (rα3β2-nAChRs). Two bioassays were used to test the efficacy of KTM. First, a qualitative
PC12 cell-based assay confirmed that KTM acts as a nAChR antagonist. Second, bioactivity
evaluation by two-electrode voltage clamp electrophysiology was used to measure the inhibition
of rα3β2-nAChRs by KTM (IC50 = 0.19 ± 0.02 nM), and inhibition of the same nAChR isoform by
α-CTx MII (IC50 = 0.35 ± 0.8 nM). The three-dimensional structure of KTM was determined by NMR
spectroscopy, and the final set of 20 structures derived from 32 distance restraints, four dihedral
angle constraints, and two disulfide bond constraints overlapped with a mean global backbone
root-mean-square deviation (RMSD) of 1.7 ± 0.5 Å. The structure of KTM did not adopt the disulfide
fold of α-CTx MII for which it was designed, but instead adopted a flexible ribbon backbone and
disulfide connectivity of C2–C16 and C3–C8 with an estimated 12.5% α-helical content. In contrast,
α-CTx MII, which has a native fold of C2–C8 and C3–C16, has an estimated 38.1% α-helical secondary
structure. KTM is the first reported instance of a Framework I (CC-C-C) α-CTx with ribbon connectivity
to display sub-nanomolar inhibitory potency of rα3β2-nAChR subtypes.
Keywords: α-conotoxin; nicotinic acetylcholine receptor; NMR; two-electrode voltage clamp
electrophysiology; PC12 cell; DockoMatic

1. Introduction
Conotoxins are 10–50 amino acid peptide toxins present in the venom of predatory marine snails of
the genus Conus. With sequence hypervariability and disulfide bond constrained scaffolds, conotoxins
have a complex classification system of 28 superfamilies, segregated in part by activity on ion channels
present in excitable tissues such as nerve and muscle [1]. α-Conotoxins (α-CTxs) target ligand-gated
nicotinic acetylcholine receptor (nAChR) ion channels and inhibit ion flow by causing a dynamic
structural change upon binding that results in the closing of the channel. nAChRs are pentameric
transmembrane channel proteins that form different combinations of homo and heteropentameric
subtypes, leading to a range of functions and ligand specificity across the host. nAChRs are found in
many tissues including muscle and the central and peripheral nervous systems, and perform numerous
physiological functions, such as the modulation of neurotransmitter release in the central nervous system
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by post and presynaptic excitation [2]. In the modulation of neurotransmitter release, acetylcholine
activation of presynaptic nAChRs causes sodium influx and subsequent cellular depolarization,
resulting in the activation of voltage-gated calcium channels and an influx of calcium ions that initiates
a signaling cascade ending in the release of dopamine-containing vesicles. Because of their involvement
in neurotransmitter release, nAChRs play a central role in the pathology of Parkinson’s disease and
other neurological disorders. For example, Parkinson’s disease patients experience a degradation of
neurons expressing α6α4β2β3-nAChRs and consequently display symptoms reflecting loss of function
dependent on dopamine release. Targeting specific nAChR isoforms is a promising strategy in the
development of improved drug therapies for Parkinson’s disease and other neurological diseases,
including Alzheimer’s, Tourette’s, and Schizophrenia [3–7]. However, there still exists a gap in
understanding of the mechanism of nAChR–ligand binding.
α-CTxs possess rigid scaffolds and are among the most potent inhibitors of nAChRs, making them
insightful molecular probes for the elucidation nAChR binding paradigms. α-CTx structure–activity
relationships have been developed for α-CTxs and their analogs, leading to the discovery of
disease-relevant nAChR subtypes and the identification of new ligand–nAChR binding sites [8–10].
Model systems used to study nAChR–ligand binding include pheochromocytoma (PC12) cell
assay [11], electrophysiology [12], mouse brain studies [13–15], and computational molecular dynamics
simulations [9,16–27]. Expression systems for studying nAChRs in vitro often prove costly and
complex [28–31], highlighting the potential value of computational studies. Emerging computational
strategies can produce promising results for nAChR ligands, but potential small molecule drugs require
evaluation by functional experimentation. Here, we present the validation results of a computational
study that used the genetic algorithm managed peptide mutant screening (GAMPMS) program in
DockoMatic v. 2.1 to predict the sequence for an α-CTx MII analog for optimal binding to the rat (r)α3β2
nAChR isoform; the outcome of the computational study was the designed peptide KTM [16–18].
DockoMatic is an open source program with an intuitive user interface to run software applications
for ligand and receptor structure file creation, perform high throughput virtual screening, and output
docking results ranked in order from best to worst binding affinity [19–21,32–34]. DockoMatic uses
the highly innovative GAMPMS algorithm specifically designed for peptide library creation, and can
correlate peptide structure to drug identity by way of the small-molecule peptide-influenced drug
repurposing (SPIDR) utility that permits screening of molecular databases using a template structure
derived from a peptide scaffold [16–18]. Previously, the GAMPMS algorithm was used to evaluate
the binding affinity of over 41 billion combinations of α-CTx MII mutants for a homology model of
the rα3β2 nAChR isoform [17]. α-CTx MII was selected as a template for this study because it has
been well characterized as a very potent and selective inhibitor of the rα3β2 nAChR isoform. α-CTx
MII is a 16 amino acid peptide with the primary sequence GCCSNPVCHLEHSNLC and disulfide
bonds between C2–C8 and C3–C16. The globular structure of α-CTx MII is characterized by an
α-helix initiated at P6 and ending at H12, providing the peptide with approximately 40% α-helical
content. The GAMPMS program was used to change the primary sequence of α-CTx MII to create a
peptide library of nearly 41 billion unique α-CTxs [17]. All amino acids were varied in the primary
sequence with the exception of the four cysteine residues required to form disulfide bonds, and the
conserved proline at position 6 required for initiation of the α-helix. Molecular docking in DockoMatic
ranked the peptides by highest binding affinity for the rα3β2 nAChR isoform. The top fifty mutant
peptides with highest affinity for the receptor were compared for amino acid identity at each site
in the peptide primary sequence to generate a consensus peptide. Figure 1A,B shows the sequence
and disulfide connectivity of KTM (A), and the sequence comparison of KTM to α-CTx MII (B).
The consensus peptide, given the arbitrary name KTM (Figure 1A; dashed), represents a rationally
designed peptide ligand that was computationally predicted to have enhanced binding affinity for the
rα3β2 nAChR isoform.
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Figure 1. (A) Sequence of KTM with globular disulfide bond connectivity of C2–C8 and C3–C16
(dashed line), and disulfide bonding from oxidative folding following solid phase peptide synthesis of
ribbon connectivity C2–C16 and C3–C8 (solid line). (B) Sequence comparison of KTM to α-CTx MII.
Of the 10 residues in α-CTx MII that were allowed to vary in the genetic algorithm managed peptide
mutant screening (GAMPMS) algorithm (orange), all but one amino acid (S13, boxed) changed to give
the sequence of KTM.

The sequences of α-CTx MII and KTM both contain 16 amino acids (Figure 1B). α-CTx MII has a
Framework I cysteine pattern of CC-C-C, consisting of two disulfide bonds between C2–C8 and C3–C16,
making it a globular connectivity pattern, and a 4/7 loop sequence common to many α-CTxs [35].
The design of KTM was inspired by the pharmacological features present in α-CTx MII and was
anticipated to adopt the same globular disulfide connectivity. KTM activity on nAChRs was assessed
qualitatively by an in vitro cell-based PC12 luminescence assay, and quantitatively for inhibition of
rα3β2 nAChR isoforms using two-electrode voltage clamp electrophysiology. KTM demonstrates
remarkable sub-nanomolar inhibition of selective nAChR subtypes, commensurate with that of α-CTx
MII. In the present study, we show that synthetic KTM produced by undirected folding preferentially
forms ribbon C2–C16 and C3–C8 disulfide linkages. In their review, Akondi, et al. suggest that correct
folding of synthetic peptides is critical to the maintenance of biological activity [35], but in the case of
KTM, the globular disulfide pattern is not the same as that found in α-CTx MII, but rather resembles
that of the ribbon isomer of α-CTx AuIB [36,37]. The net effect of the disulfide connectivity is that α-CTx
MII adopts a globular scaffold, while KTM is consistent with ribbon-connectivity. Solution nuclear
magnetic resonance (NMR) spectroscopy was used to determine the three dimensional structure of the
synthesized KTM for comparison to α-CTx MII and the computationally predicted structure. Molecular
dynamics simulations in Gromacs were used to assess peptide dynamics.
2. Results
2.1. Bioactivity
KTM was qualitatively evaluated for nAChR bioactivity using a PC12 cell assay; antagonist activity
by KTM in the presence of acetylcholine (ACh) was confirmed (Figure 2), prompting quantitative
evaluation of bioactivity by electrophysiology. In the preliminary screening qualitative assay, ACh
is used to stimulate PC12 cells, opening nAChR channels, resulting in dopamine release [38,39].
Following release, dopamine is oxidized by monoamine oxidase, generating hydrogen peroxide that
catalyzes a chemiluminescence reaction involving luminol and horseradish peroxidase, producing a
detectable response. Incubation with α-CTxs prior to stimulation with ACh inhibits nAChRs, resulting
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in a diminished signal, as is observed for treatment with α-CTx MII (see Figure 2). A decreased signal
resulting from treatment with KTM indicates that nAChRs are inhibited by this compound.

Figure 2. Qualitative PC12 assay luminescence responses upon stimulation of nicotinic acetylcholine
receptors (nAChRs) with acetylcholine (ACh), with and without 10 µM toxin. Assays performed with
the addition of α-CTx MII and KTM resulted in a diminished luminescence recording compared to an
ACh control.

Two-electrode voltage clamp experiments were used to determine the IC50 for KTM on rα3β2
nAChRs expressed in Xenopus laevis oocytes. Figure 3A shows responses to local application of ACh
prior to (left) and following (right) toxin exposure. The concentration-dependent curves for inhibition
of rα3β2 nAChR by MII and KTM are shown in Figure 3B. KTM exhibited potent inhibition with an
IC50 of 0.19 ± 0.02 nM commensurate with α-CTx MII with an IC50 of 0.35 ± 0.08 nM. α-CTx MII and
KTM have Hill coefficients of 0.5 and 0.7, respectively.

Figure 3. Responses to the local application of ACh for 30 ms are shown for control and after 3 nM
toxin application; calibration horizontal 2 sec, vertical 1 µA (A). Concentration-dependent response
curves for blocking rα3β2 nAChR by α-CTx MII (red) and KTM (blue) (B). Hill coefficients for the
concentration response curves of α-CTx MII and KTM are 0.5 and 0.7, respectively. IC50 values of KTM
and α-CTx MII are 0.19 ± 0.02 nM and 0.35 ± 0.08 nM, respectively. Data are means ± SEM from eight
to 12 trials.
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2.2. Structure Determination
Analysis of the circular dichroism (CD) spectrum for KTM (Figure 4, double lined grey) gave
a predicted α-helical content of 12.5%, consistent with the ribbon-type isomer fold (C1–C4; C2–C3),
and not the expected globular-type fold (C1–C3; C2–C4) characteristic of α-CTx MII, for which the
α-helical content is 38.1% (Figure 4, solid black line). The large negative peak commonly observed for
α-CTxs corresponds to the α-helical portion of the peptide, and is predominantly absent in the CD
spectrum of KTM. The interpretation of CD spectra for flexible small peptides is representative of an
ensemble of conformations, so it is difficult to draw definitive secondary structure conclusions based
solely on CD data. The CD data in Figure 4 did identify variation in the secondary structure between
KTM and α-CTx MII that brought into question the disulfide connectivity in KTM, necessitating
framework determination for KTM by partial reduction mass spectrometry.

Figure 4. The circular dichroism (CD) spectrum of α-CTx MII (solid black line) and KTM (double
lined grey). Measurements for each peptide were taken in water at 50 µM, and a pathlength of 1 mm.
The α-helical content of α-CTx MII and KTM were estimated to be 38.1% and 12.5%, respectively,
as calculated from the observed signal at 222 nm.

Partial reduction by TCEP of 100 pmol of synthetic KTM peptide gave expected product profiles in
LC-MS chromatograms with mass increases corresponding to partial reduction (+2 m/z) and alkylation
(NEM, +125 m/z; IAA, +59 m/z) (see Materials and Methods). Sequence analysis showed the disulfide
bridging pattern was not consistent with the expected α-CTx C2–C8/C3–C16 globular linkage as found
in α-CTx MII, but rather a C2–C16/C3–C8 ribbon linkage (Figure S1), as observed in α-CTx AuIB [36,37].
NMR structure determination for KTM was performed to compare the computationally predicted
C2–C8/C3–C16 globular structure to the synthesized C2–C16/C3–C8 ribbon structure. Assignment
of 1 H resonances for KTM was achieved using standard methods [40]. A combination of COSY,
TOCSY, and NOESY spectra in both 30% ACN/70% water and 30% ACN/70% D2 O were used to reduce
ambiguities in assignment. Fifteen amino acid spin systems were assigned in the fingerprint region
(7.6–8.8 ppm), and the final amino acid, P6, was identified in the α-proton region (5.2–3.8 ppm). Table 1
shows the chemical shift assignments for each of the sixteen amino acids in KTM, and Figure 5 shows
the calculated random coil chemical shift difference. Table 2 shows the 32 nuclear Overhauser effect
(NOE) distance restraints, four dihedral angles, and two disulfide bond constraints that were input
into CYANA for structure calculation. NMR structure determination using CYANA [41] confirms the
peptide backbone exists as a ribbon, lacking a defined α-helix. Despite a reasonably rigid scaffold
constrained by two disulfide bonds, the backbone structure of KTM reflects the influence of side chain
mobility particularly evident for the aromatic Tyr and Trp residues. Figure 6 A-B shows a comparison
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of the NMR-derived structures (A), and an overlay of the median NMR-derived structure (cyan) to the
computationally predicted structure (magenta) for KTM (B). The root-mean-squared deviation (RMSD)
for backbone atoms to a mean structure was calculated to be 1.7 ± 0.4 Å (Figure 6A). The RMSD
between the NMR solution structure of KTM and the computationally predicted KTM structure was
3.5 Å, which is expected considering the computationally predicted structure maintained the globular
disulfide connectivity consistent with α-CTx MII (Figure 6B).
Table 1. Proton chemical shift assignments for amino acids in KTM.
Residue

NH

αH

βH

Other

W1

8.31

4.62

3.61,3.44

2H 7.37, N1H 10.23

C2

8.57

5.33

3.71,2.92

C3

8.63

5.14

2.96,3.67

S4

8.53

4.23

3.97

Y5

7.91

4.84

3.39,3.23

4.07

1.99,2.20

P6

δH 3.70,3.58

G7

7.96

4.08

C8

8.40

4.53

3.62,3.11

Y9

7.78

4.57

3.32,3.60

W10

8.09

4.84

3.21

S11

8.62

4.33

3.83

S12

8.38

4.25

3.88

S13

8.74

4.40

4.01

K14

8.19

4.66

1.72,1.56

δH 1.39, γH 1.29, εH 2.91, N2H 8.00

W15

7.64

5.12

3.13,3.31

2H 7.48, N1H 10.33

C16

8.47

5.08

3.57,3.04

2H 7.74, N1H 10.52, 7H 7.88

Figure 5. Chemical shift difference between α-protons of amino acids in KTM and predicted random
coil chemical shifts for the same amino acids.
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Table 2. Nuclear magnetic resonance (NMR) restraints used in CYANA, and the resulting structure
statistics for KTM.
Experimental Data
Distance Restraints
Total NOE

32

Intra-residue

12

Inter-residue

20

Sequential

18

Short range

30

Medium range

2

Long range

0

φ Dihedral angle restraints

4

Disulfide restraints

2

Total NOE violations exceeding 0.3 Å

0

Total NOE violations exceeding 0.3 Å

0

Structure Statistics
Average pairwise RMSD (Å)
Backbone atoms (residues 1–16)

1.7 ± 0.5

Heavy atoms (residues 1–16)

3.0 ± 0.7

Ramachandran statistics
%Favored and allowed regions

100

%Disallowed regions

0

Figure 6. NMR solution structure of KTM, where (A) is a ribbon representation of an ensemble
of the 20 lowest energy structures, with an average RMSD to the mean structure of 1.7 ± 0.4 Å,
and (B) represents an overlay of the mean calculated structure from NMR (cyan) and the computationally
predicted structure (magenta) that have an average RMSD of 3.5 Å.

2.3. Molecular Dynamics Simulations
Figure 7 shows the root-mean-square fluctuations (RMSFs) for each residue after a 50 ns molecular
dynamics simulation in Gromacs. According to these results, the side chains of KTM are expected
to have a high degree of fluctuation. Residues W1, S4–G7, and K14, particularly, show the highest
degrees of fluctuation.
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Figure 7. Root mean square fluctuations for each of the 16 residues of KTM over a 50 ns MD
simulation. Residues W1, S4–G7, and K14 were observed to exhibit the greatest root-mean-square
fluctuations (RMSFs).

3. Discussion
Qualitative evaluation of KTM bioactivity with the PC12 assay confirmed that KTM reduced
the amount of dopamine released from the cells, presumably by blocking nAChRs (Figure 2) [11].
To assess whether KTM acted on rα3β2-nAChRs, as it was designed to do, quantitative evaluation of
its bioactivity was performed by two-electrode voltage clamp electrophysiology using Xenopus oocytes
expressing rα3β2-nAChRs. KTM caused blockage of rα3β2-nAChRs with an IC50 of 0.19 ± 0.02 nM as
compared to 0.35 ± 0.08 nM for α-CTx MII (Figure 3). The similar efficacy of KTM compared to that of
α-CTx MII supports the premise that the synthetic peptide is an effective antagonist of rα3β2-nAChR.
KTM exhibited potent inhibition of rα3β2-nAChRs commensurate with α-CTx MII, necessitating
validation of synthetic peptide structure for comparison to the computationally predicted structure.
The primary sequence of KTM differs from α-CTx MII with regard to nine of the sixteen amino acids.
First, the NMR structure of KTM was determined using the method established by Wüthrich [40].
Sequence, distance, dihedral angle, and disulfide bond restraints were entered into CYANA for
structure calculation. It was anticipated that the disulfide bonds in synthesized KTM, that were
formed by undirected folding, and those of native α-CTx MII, would be consistent. Despite extensive
analysis of NMR data and restraint assignment, CYANA failed to provide an ensemble of KTM
backbone structures that converged better than a RMSD of 2.5 Å. An evaluation of the CD spectrum
and partial reduction mass spectrometry data provided definitive evidence that the disulfide pattern
for KTM synthesized by undirected folding was not the same as the globular fold of α-CTx MII (C1–C3,
C2–C4), but rather was consistent with the ribbon fold observed for an isomer of α-CTx AuIB (C1–C4,
C2–C3) (see Figure S1). An ordered secondary structure commensurate with the common α-CTx
4/7 loop peptide α-helix of MII was not expected due to the α-helical content for KTM interpreted
as 12.5% based on CD spectrum, which is much lower than the α-helical content for α-CTx MII of
38.1% (Figure 4). Upon changing the disulfide bond connectivity restraints in CYANA, a final set
of 20 KTM structures with an RMSD among backbone atoms of 1.7 ± 0.5 Å was obtained with no
distance restraint or conformation violations detected (Figure 6). The RMSD between the NMR solution
structure of KTM and the computationally predicted structure of KTM was 3.5 Å. The rough similarity
in backbone shape between the computationally predicted and NMR solution structure generated
for KTM, despite differing disulfide linkages, is suspected to be the reason for the observed nAChR
bioactivity. Preliminary analysis of NMR data for chemical shift deviation from random coil was used
as an indication of expected KTM peptide rigidity (Figure 5). Random coil peptides generally show
amide proton chemical shifts between 8.09 and 8.45 ppm [42], while those in KTM were between
7.64 and 8.74, indicating regions of structure rigidity. Similarly, random coil peptides generally show
α-proton chemical shifts between 4.4 and 4.8 ppm, while those in KTM were between 4.07 and 5.33 ppm.
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Thus, the chemical shift variation observed for amide and α-protons in KTM (Figure 5) were consistent
with data expected for a peptide of reasonably rigid scaffold.
The relatively low number of distance and angle constraints for KTM was due to challenges
associated with a 1942 Da peptide and the high redundancy of amino acids (4C, 4S, 3W, 2Y), resulting
in many proton chemical shifts in similar or identical electronic environments. The interpretation of
NMR spectra for KTM was severely complicated due to peak overlap, ring-flipping of aromatic side
chains, and spectral shift between H2 O and D2 O spectra. Figure 8 shows an overlay of the fingerprint
region for COSY and TOCSY spectra used to assign the spin systems in KTM from which the chemical
shift assignments as summarized in Table 1 were generated. The proton chemical shifts for aromatic
amino acids are largely missing from Table 1 due to assignment ambiguity originating from the three
tryptophan and two tyrosine residues with overlapping chemical shifts further exacerbated by ring
flipping. Additional structure challenges arose from the molecular weight of KTM correlating to
the NOE detection minimum, limiting the number of medium- and long-range NOEs that could be
assigned as restraints. Conotoxin structure determination by NMR is inherently difficult due to weak
NOE signals, limited distance for protons to provide an assignable NOE, and side chain mobility that
provides conformations where protons enter in and out of detectable proximity to one another [43].
Additionally, the high number of heavy aromatic side chains in KTM is suspected to contribute to
inherent flexibility.

Figure 8. Fingerprint region of COSY (red) and TOCSY (grey) spectra overlaid for residues 1–5 and
7–16, acquired at 600 MHz for KTM at 298 K in 30% ACN/70% H2 O. Residue assignments are indicated
by their one-letter amino acid code.

Perhaps the most striking finding of this study was that KTM, which was predicted to act on
rα3β2-nAChRs, did indeed do so, and with very high potency, despite having a ribbon-type α-CTx
disulfide connectivity. There is precedent for ribbon isomers of Framework I α-CTxs with binding
affinity for rα3β2-nAChRs. Dutton, et al. (2002) characterized a non-native ribbon disulfide bond
isomer of recombinant α-CTx AuIB that, while more flexible than the native globular isomer, exhibited
10 times more potent activity with nAChRs in rat parasympathetic neurons than the native globular
isomer [36,37]. They presumed that the flexibility of the ribbon isomer allowed the peptide to adopt a
complementary conformation with the receptor binding site. KTM is the first example of a Framework I
α-CTx with ribbon fold to demonstrate sub-nanomolar inhibition of rα3β2-nAChRs. To briefly explore
why KTM exhibits functionality consistent with α-CTx MII, a comparison of the electrostatic maps
of α-CTx MII and KTM was performed using the ABPS Electrostatics plugin in PyMOL [44] after
performing a 50 ns molecular dynamics simulation in Gromacs. The simulation shows that the side

Mar. Drugs 2019, 17, 669

10 of 18

chains for W1, S4–G7, and K14 have a high degree of fluctuation (Figure 7), and that loop 2 is especially
dynamic (Figure 9), indicating that a single model may not well represent the peptide.

Figure 9. Ribbon structures of KTM at 0 ns (left), 25 ns (middle), and 50 ns (right) in the molecular
dynamics simulation. Loop 2 appears to swing across the peptide over the course of the simulation.

Figure 9 shows the progression from left to right of representative structures through the course
of a molecular dynamics simulation with snapshots taken at 0, 25, and 50 ns run time. The dynamic
movement of the second loop is exemplified throughout the course of the MD trial. To illustrate the
dynamic flexibility of KTM and its potential for induced fit into the binding site of rα3β2 nAChR,
the electrostatic surfaces of KTM at 0 ns (Figure 10A) and at 50 ns (Figure 10C) are shown in comparison
to α-CTx MII (Figure 10B). KTM can adopt both a structure with a surface volume much larger than
α-CTx MII with multiple points of protrusion from aromatic side chains and a hollow core (Figure 10A),
as well as a more compact structure that more closely resembles that of α-CTx MII as loop 2 appears to
flex inward (Figure 10C).

Figure 10. Electrostatic maps of KTM at 0 ns of the molecular dynamics simulation (A), α-CTx MII (B),
and KTM at 50 ns of the molecular dynamics simulation (C). Images on the left and right are rotated by
180 degrees.

Figure 10 shows the convergence from NMR-derived structure (0 ns MD, A) to computationally
refined KTM conformation upon 50 ns simulation (C), compared to the structure of α-CTx MII
(B). The MD simulation provides correlation between KTM and MII that reflects common surface
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electrostatics and structure topography attributes that may be used to explain the observed potent
activity of KTM on nAChRs (Figure 3).
4. Materials and Methods
4.1. Synthesis
KTM was synthesized by and purchased from CS Bio (Menlo Park, CA) in folded form as a white
powder. Following solid phase peptide synthesis, disulfide linkages were allowed to form into the most
thermodynamically stable conformation under reducing conditions. The major isomer was collected
by HPLC at ca. 98.36% purity. The peptide was collected at 10.71 min using a 20%–50% gradient of
Buffer B (0.1% TFA in ACN) over a 20 min run time, where Buffer A was 0.1% TFA in H2 O. The column
was a Phenomenex Luna C18 with specifications of 5 µM, 100 Å, 4.6 ×250 mm. The flow rate was
1 mL/min and the injection volume was 20 µL. Peptide identity was confirmed by mass spectrometry
where the expected molecular weight was 1942.21 Da and the found molecular weight was 1941.52 Da.
4.2. Disulfide Bond Analysis
Analysis was performed using an UltiMate 3000 HPLC (Thermo Scientific, Waltham, MA, USA)
equipped with a Corona Veo RS charged aerosol detector (CAD), an UltiMate 3000 Diode Array
Detector (DAD), and MSQ Plus mass spectrometer (MS). HPLC separation of peptide species was
achieved using an Acclaim 120 C18 column (2.1 × 150 mm, 3 µm) (Thermo Fisher), and mobile phases
consisting of 0.1% formic acid (v/v) in water (Buffer A) and 0.1% formic acid (v/v) in acetonitrile (Buffer
B) with a flow rate of 0.3 mL/min. A linear gradient method beginning at 85% Buffer A and 15%
Buffer B, up to 60% Buffer B over a 25 min run time achieved desired separation from a 10 µL sample
injection volume. Data were analyzed with the Chromeleon 7.2 Chromatography Data System (Thermo
Fisher). The partial reduction strategy of Gray [45] was used to sequentially reduce and alkylate
disulfide bonds. Synthetic KTM peptide (0.1 nmol) from CS Bio was dissolved in 1 M equivalent
of tris 2-carboxyethyl phosphine (TCEP) in 25 mM ammonium formate, at pH 4.5, and incubated
at 37 ◦ C for 10 min. Following incubation, the reaction mixture was separated by HPLC, and the
peptide reduction was monitored by mass spectrometry through observation of a mass increase of
+2 m/z, corresponding to the peptide with one disulfide bond reduced. Two molar equivalents of
N-ethylmaleimide (NEM) were added and the reaction mixture and alkylation was monitored by
LC-MS for observation of a mass increase of +125 m/z. The increase in m/z of +125 in the doubly
charged ion equates to a mass shift of +250 Da in KTM corresponding to the coupling of one thiol
to NEM. Peptide fractions, as identified by UV absorbance at 280 nm, were collected manually into
1.5 mL polypropylene centrifuge tubes and lyophilized to dryness. The resultant di- and tetra-alkylated
peptides appeared as dull white powders. Monocyclic intermediates were reconstituted in 1:1 (v/v)
acetonitrile/25 mM ammonium formate, reduced with dithiothreitol (DTT) at a final concentration of
10 mM for 1 hr at 37 ◦ C, and alkylated with iodoacetamide (IAA) at a final concentration of 55 mM for
1 hr in the dark at room temperature. The reaction mixture was injected onto the LC-MS to monitor
reduction and alkylation by observation of a mass increase of +59 m/z, corresponding to the addition of
acetamide. Doubly alkylated peptides were submitted for sequence analysis to determine the locations
of S-carboxamidomethyl-L-cysteine residues, and confirm the disulfide connectivity (see Figure S1).
MS/MS fragmentation for sequence analysis was achieved using a Velos Pro Dual-Pressure Linear
Ion Trap mass spectrometer (Thermo Scientific) coupled to a Nanoscale LC system at a flow rate of
300 nL/min. A fused silica emitter directly attached to the analytical column through a zero dead volume
union was used to spray peptides at a voltage of 2.2 kV. MS/MS data was collected in data-dependent
acquisition mode, using collision-induced dissociation (CID) with a normalized collision energy of
35% to fragment the precursor ions. MS/MS data for the 10 most abundant precursor ions was selected
from the proceeding full MS scan over the m/z range of 300–2000. Proteome Discoverer 2.2 (Thermo
Scientific) was used to analyze the data.
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4.3. Circular Dichroism Spectropolarimetry
Circular dichroism (CD) spectra were recorded on a Jasco J-810 spectropolarimeter (Jasco, Inc.,
Easton, MD, USA) with a cell path length of 0.1 cm at room temperature in a nitrogen atmosphere
in water. Scans were acquired from 190 to 250 nm. The bandwidth of 1 nm, a speed of 50 nm/min,
and a resolution of 0.5 nm were used. A total of 5 scans per sample were averaged, baselines were
subtracted, and the sample was run in triplicate. A final concentration of 50 µM of each sample was
used. Analysis and data processing were carried out with the Jasco system software and Microsoft
Excel. Mean residue ellipticity (θMRE, in deg × cm2 × dmol−1 ) for each spectrum was calculated from
the formula θMRE = θ/(10Cr × l), where θ is the measured ellipticity in millidegrees, Cr is the molar
concentration, and l is the path length in centimeters. The α-helical content was estimated from the
formula θMRE = 30300fH–2340, where fH is the fraction of α-helical content (fH × 100, expressed as a
percentage) calculated from the θMRE at 222 nm, which is a widely used proxy for helical secondary
structure that is useful to assess disruption of the secondary structure, as was performed here [46–48].
4.4. Nuclear Magnetic Resonance Spectroscopy
NMR samples were prepared at a concentration of approximately 3 mM in either 30% deuterated
acetonitrile (d-ACN)/70% water or 30% d-ACN/70% deuterium oxide (D2 O). d-ACN was used due
to the limited solubility of KTM in water. D2 O samples were prepared by dissolving lyophilized
sample in 30% d-ACN/70% D2 O solvent and immediately acquiring spectra. Two-dimensional 1 H
NMR experiments and spectral interpretation were performed by established methods [40–42,49–54].
All NMR data were acquired on a 600 MHz Bruker Avance III NMR spectrometer at 298 K. COSY,
TOCSY, and NOESY spectra were acquired using water suppression for aqueous samples. A series of
NOESY spectra were acquired with mixing times of 150, 200, 250, 300, and 350 ms. TOCSY spectra
were acquired with an 80 ms mixing time (30% ACN/60% H2 O /10% D2 O). Parameter set details are
provided in Table S1. Spectra were processed in Topspin and analyzed in CCPNMR v2 and v3 [55] to
correct resonance shifts, manually pick peaks, and identify spin systems.
4.4.1. Restraint Set Generation
Three-bond 1 HN -1 Hα coupling constant values were determined by visual inspection of a
high-resolution 1D 1 H spectrum in Topspin. Backbone dihedral phi angle restraints were set to
−120 ± 40 for 3 JHH 1 HN -1 Hα coupling constant values greater than 7.5 Hz and to −65 ± 25 for 3 JHH
1 HN -1 Hα coupling constant values less than 5 Hz [54]. Inter- and intraproton distance ranges were
calibrated within CYANA. Distance restraints were derived from NOESY spectra recorded at 298 K
and mixing time of 350 ms.
4.4.2. Structure Calculation
Input files were formatted for the CYANA program (v 2.1). The autoassign script in CYANA was
used for assignment of 69 hydrogen atom chemical shift values. A chemical shift tolerance of 0.075 was
used for both axes. Disulfide bonds were used as distance restraints. CYANA produced an ensemble of
20 top structures based on 32 restraints. The final set of 20 structures gave a root-mean-square deviation
among backbone atoms of 1.7 ± 0.4 Å. The structure most representative of the mean structure was
determined with WHATIF [56]. Procheck [57] and Verify3D [58] online servers were used to assess
structure quality. Molprobity scores are reported in Table S2 [59].
4.5. PC12 Assay
Cell culture and bioactivity assessment were performed according to Marquart, et al. [11]. The PC12
assay was performed using a Biotek Synergy H1 microplate reader (Winooski, VT). All chemicals were
purchased at the highest purity available (>95%) from Fisher Scientific. ATCC® CRL1721™ PC12 cells
were provided by the Biomolecular Research Center at Boise State University.
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4.5.1. Cell Culture
PC12 cells were cultured into laminin-coated flasks and triturated to detach. Cells were grown in
a T-75 flask until dense enough to plate onto a laminin-coated flat-bottom well plate and treated with
starvation media (30 ng/mL NGF 2.5 S, 1 µM nicotine) for 3–4 days before performing the assay.
4.5.2. Assay
Cells were washed with Locke’s solution before introducing the assay solution, which included
10 µM toxin, 0.8 ng/mL POD, 25 ng/mL MAO, and 50 µM luminol. The luminol was added to quench
any dissolved oxygen in the cell environment and the assay solution. Cells were allowed to equilibrate
for 5–10 min before the addition of 2 mM luminol and 50 µM ACh, for a total well volume of 100 µL.
Upon equilibration, the luminescence signal was detected. (-)MAO and (-)cells were used as negative
controls. Assays were performed at 37 ◦ C, detecting luminescence for 1–2 min per well. Luminescence
response curves were then integrated as a measure of dopamine secretion inhibition resultant from
peptide treatment for analysis.
4.6. Electrophysiology
4.6.1. rα3β2-nAChR expression in Xenopus laevis oocytes
cDNA preparation, oocyte harvest, expression of nAChR subunits, and culture were performed
as described previously [60]. The rat isoforms of neuronal nAChR subunits α3 and β2 in vectors
pSP64 and pSP65, respectively, were generously provided by Dr. Steven Heinemann (Salk Institute,
San Diego, CA). All salts and antibiotics were obtained from Sigma or Fisher Scientific. Oocytes
were extracted from adult Xenopus according to protocols approved by the Institutional Animal Use
and Care Committee at ISU and according to AAALAC guidelines. Oocytes were isolated with
2 mg/L collagenase and cultured at 17.5 ◦ C in sterile ND-96 saline containing 96 mM NaCl, 2 mM
KCl, 1.8 mM CaCl2 1 mM MgCl2 , and 5 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), with 5 mM Na pyruvate, 2% horse serum, 100 mg/L gentamicin, 100 mg/L amikacin, 50 mg/L
ciprofloxacin, 20 mg/L tetracycline, and 100 U/L streptomycin/penicillin, at pH 7.4. Messenger RNA
was transcribed as detailed previously; α3 and β2 mRNA was coinjected at 41 nL into oocytes 3 to
5 days prior to recordings.
4.6.2. Two-Electrode Voltage Clamp
To record the response to ACh, oocytes were impaled with glass electrodes containing 3 M
KCl for two-electrode voltage clamp electrophysiology. Oocytes were placed in a 300 µL recording
chamber and perfused at 1.0 mL/min with ND-96 saline containing atropine sulfate (1 mM), at room
temperature. Voltage clamp was performed with an OC-725C amplifier (Warner Instruments, Hamden,
CT) with data acquisition achieved through an ITC-18 interface and PatchMaster 2.35 software (HEKA
Instruments, Bellmore, NY). Oocytes were held at -70 mV between trials, and at -80 mV during trials of
ACh application. During perfusion, a 20 to 50 ms pulse of ACh chloride (0.01 M, Sigma, St. Louis,
MO) in the bath solution was locally applied from a glass capillary tube positioned above the oocyte,
with pressure ejection using a PicoSpritzer II valve controller (General Valve Corporation, Fairfield,
NJ). Once a reliable response was obtained, the chamber was perfused with α-CTx MII or KTM for
15 min, and the ACh pulse was applied. Inward sodium current amplitudes for each toxin trial were
normalized against the control response to ACh as percent response. Each data point of the dose
response curve represents the average value of 8 to 12 measurements. Dose-dependent response curves
were fit to Equation (1):
%response = 100/[1 + ([toxin] / IC50 )n ],
(1)
where n is the Hill coefficient and IC50 is the inhibitory concentration at half-maximal block, by non-linear
regression analysis using Igor Pro 6.37 (Wavemetrics, Lake Oswego, OR, USA).
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4.7. Molecular Dynamics Simulations
Molecular dynamics simulations were performed with the AMBER03 force-field parameter set [61]
using the Gromacs 2019 software package [62]. The median conformation for KTM from the top 20
NMR solution structures was selected as the input structure for MD simulation in Gromacs. Since
the NMR spectra were acquired for a sample in 30% acetonitrile/70% water, the solvated box was
obtained by filling a dodecahedral box with the appropriate number of acetonitrile molecules to
achieve the desired mixed solvent proportions. A topology for acetonitrile was created for this purpose.
The shortest distance of peptide atoms from the box boundary was 1.2 Å. Simulations were carried out
at 300 K in a periodic box with a minimum-image convention. The integration step was 1 fs, and total
duration of each run was 50 ns. Water, acetonitrile, and ions were temperature coupled. Energy
minimizations and N, V, T and N, P, T equilibrations were performed before running the simulation.
A 500 ps equilibration was conducted under the NVT ensemble using a velocity-rescale thermostat at
300 K with a coupling time constant of 0.1 ps. A subsequent 500 ps NPT equilibration was performed
using the isotropic Berendsen barostat with a time constant of 0.1 ps. Simulations and models were
visualized in PyMOL [44].
5. Conclusions
This investigation sought to validate the accuracy and usefulness to rationally design a selective
antagonist of a specific nAChR isoform based on the well characterized marine drug α-CTx MII.
Synthetic KTM peptide was confirmed to be a potent sub-nanomolar inhibitor of rα3β2 nAChRs. It was
expected that KTM would fold into the same C1–C3 and C2–C4 disulfide pattern, consistent with α-CTx
MII. Instead, the folding of KTM resulted in a C1–C4 and C2–C3 ribbon Framework I α-CTx, consistent
with the recombinant isomer of α-CTx AuIB [36,37]. It has been stated in the literature that correct
folding of synthetic peptides is critical to the maintenance of biological activity, but in the instance of
KTM, the globular disulfide pattern is not the same as that found in α-CTx MII, but rather resembles
the ribbon-connectivity studied for α-CTx AuIB [36,37]. KTM is the first example of sub-nanomolar
nAChR antagonism by a Framework I α-CTx of ribbon-connectivity. A compelling next step for this
work would be the directed folding of KTM to assess whether the potency of the globular-connectivity
Framework I peptide may be further enhanced for nAChR inhibition. Validation of computationally
predicted peptide binding and biological activity may lead to a better understanding of molecular
probes for the treatment of neurological diseases like Parkinson’s Disease. Drugs that selectively
target human α6α4β2β3 nAChR isoforms could be used as new therapies with fewer side effects than
existing treatments. The current study offers a workflow to begin the search for drug therapies inspired
by marine natural products.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/17/12/669/s1,
Table S1: Parameter set details for NMR experiments.; Table S2: Molprobity scores for NMR ensemble; Figure S1:
Annotated MS-MS spectrum of relevant distinguishing B and Y fragments.
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